Shaping the Future of Therapeutics

Data/AI Driven Drug Discovery

Speaker - Funded(s)

• 

  Andreas Bender

  Professor
  Cambridge University
  Cambridge, England, United Kingdom

Speaker - Not Funded(s)

• 

  James Dunbar, DPhil (he/him/his)

  VP Discovery Technology
  BenevolentAI
  London, England, United Kingdom
• TJ

  Thomas Jones

  Senior Scientist
  AstraZeneca
  CAMBRIDGE, England, United Kingdom

This session centres on the transformative impact of data science and artificial intelligence (AI) in drug discovery. The focus will be on the application of machine learning, data analytics, and computational models for tasks such as identifying novel drug targets and optimizing lead compounds. Sessions will address the journey from data acquisition to actionable insights, emphasizing the development of robust algorithms and the validation of AI models.

Presentations:

• 14:30 – 15:00 CEST

  AI in Drug Discovery - Approaches, Current Status, and Challenges
  

  Andreas Bender – Cambridge University
• 15:00 – 15:30 CEST

  Putting large language models into action for target Identification
  

  James Dunbar, DPhil (he/him/his) – BenevolentAI
• 15:30 – 16:00 CEST

  Automating the DMTA cycle in Astrazeneca
  

  Thomas Jones – AstraZeneca